Adaptive OSK Expression Guided by Real-Time Epigenetic Clock Feedback

Hypothesis: Coupling the LUC methylation clock (or a tissue‑specific ribosomal clock) to a synthetic doxycycline‑responsive OSK circuit creates a closed‑loop system that dynamically adjusts OSK dosage to keep epigenetic age within a predefined rejuvenation window, thereby maximizing rejuvenation while avoiding pluripotency or tumorigenic risks.

Mechanistic Rationale: OSK‑mediated demethylation depends on TET1/2 activity and occurs within 4‑7 days, producing a measurable shift in clock readouts 1 4. If the clock output (e.g., luminescence from a LUC‑driven reporter) falls below a set threshold indicating sufficient demethylation, a methyl‑sensitive promoter driving the rtTA transactivator is attenuated, reducing doxycycline‑induced OSK transcription. Conversely, when clock signal remains high (indicating older epigenetic state), rtTA expression is sustained, maintaining OSK expression. This creates a negative‑feedback loop that mirrors homeostatic control of hormone axes.

Novel Components:

• A LUC‑responsive element (CpG‑rich promoter whose activity inversely correlates with methylation) placed upstream of rtTA.
• A tet‑On OSK cassette (polycistronic TRE‑OSK) already validated in AAV9 2.
• An optional safety switch: a Nanog‑promoter‑driven CRISPRi targeting OSK, activated only if pluripotency markers emerge.

Testable Predictions:

1. In aged mice receiving AAV9‑LUC‑rtTA‑OSK, longitudinal bioluminescence will show a rapid decline during the first week, followed by a plateau that matches the epigenetic age reversal measured by bulk LUC clock sequencing.
2. Animals with the feedback loop will exhibit a narrower distribution of epigenetic age across individuals compared with fixed‑duration OSK groups, reflecting individualized dosing.
3. The incidence of Nanog expression or tumorigenic lesions will be significantly lower in the feedback group than in cohorts receiving constant OSK for equivalent cumulative exposure.
4. When the feedback loop is disrupted (e.g., by mutating the CpG sites in the LUC‑responsive element), OSK expression will revert to open‑loop kinetics, leading to either under‑dosing (insufficient age reversal) or over‑dosing (transient Nanog upregulation), falsifying the hypothesis.

Experimental Design:

• Group A: AAV9‑TRE‑OSK + constitutive rtTA (standard 4‑week doxycycline).
• Group B: AAV9‑LUC‑rtTA‑OSK (feedback).
• Group C: AAV9‑LUC‑rtTA‑OSK with mutated CpG sites (open‑loop control). Measure doxycycline intake, OSK mRNA, bioluminescence, LUC clock sequencing, frailty index, lifespan, and histology for tumors at 6 months.

Falsifiability: If Group B does not show improved precision of epigenetic age reversal, increased safety, or comparable efficacy to Group A, the hypothesis that real‑time clock‑guided dosing enhances OSK therapy is refuted.

This approach translates the predictive power of methylation clocks from retrospective biomarkers to active, therapeutic regulators, addressing the current translational bottleneck of fixed OSK regimens.